Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole

Matthew J Ellis, Yu Tao, Oliver Young, Sharon White, Alan D Proia, Julliette Murray, Lorna Renshaw, Dana Faratian, Jeremy Thomas, Mitch Dowsett, Andreas Krause, Dean B Evans, William R Miller, J Michael Dixon

Research output: Contribution to journalArticlepeer-review

Abstract

To investigate the impact of human epidermal growth factor receptor (HER) 1 and HER2 gene amplification on endocrine therapy responsiveness, a fluorescence in situ hybridization (FISH) study was conducted on tumor samples from 305 postmenopausal patients with stage II and III estrogen receptor (ER) -positive (ER > or = 10%) breast cancers treated on two independent neoadjuvant endocrine therapy trials.
Original languageEnglish
Pages (from-to)3019-25
Number of pages7
JournalJournal of Clinical Oncology
Volume24
Issue number19
DOIs
Publication statusPublished - 1 Jul 2006

Keywords

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Breast Neoplasms
  • Cell Proliferation
  • Female
  • Gene Amplification
  • Genes, erbB-1
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Middle Aged
  • Neoadjuvant Therapy
  • Nitriles
  • Receptor, erbB-2
  • Receptors, Estrogen
  • Treatment Outcome
  • Triazoles
  • Tumor Markers, Biological

Fingerprint Dive into the research topics of 'Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole'. Together they form a unique fingerprint.

Cite this